Granules India Limited Overview
Pro stress-test →Granules India manufactures and sells Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. Founded in 1984 and headquartered in Hyderabad, Telangana, the company specializes in producing large-scale quantities of common pharmaceuticals. The company is navigating a critical period with significant regulatory challenges alongside strategic growth initiatives.
Strategic Profile
Pro stress-test →Granules is completing remediation efforts at its Gagillapur facility while investing in R&D for ADHD and oncology treatments, alongside peptide synthesis capabilities. The company faces operational challenges driven by integration costs from the Senn Chemicals acquisition and ongoing regulatory compliance expenses.
Competitive Landscape
Pro stress-test →The company has delivered poor sales growth of 11.5% over the past five years. Granules competes in the generic API and finished dosage market against larger integrated pharma companies like Cipla, Aurobindo, and Lupin, as well as specialized API manufacturers. The company is differentiating through complex generic formulations (ADHD, oncology) and peptide synthesis capabilities to capture higher-margin niches.
Industry Context
Granules India Limited operates in Pharmaceutical Manufacturing (APIs, Formulation Intermediates & Finished Dosages).
Key facts
Founded: 1984 · Headquarters: Hyderabad, India · Revenue: ₹1,387.9 crore (Q3 FY26) · Market cap: $1.68B (₹13,414 crore as of early February 2026)